Bank of New York Mellon Corp Purchases 149,522 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS)

Bank of New York Mellon Corp increased its position in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) by 92.2% during the 2nd quarter, Holdings Channel reports. The firm owned 311,630 shares of the company’s stock after acquiring an additional 149,522 shares during the period. Bank of New York Mellon Corp’s holdings in Pyxis Oncology were worth $1,031,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of PYXS. Fullcircle Wealth LLC bought a new stake in Pyxis Oncology during the second quarter valued at about $40,000. SG Americas Securities LLC purchased a new stake in shares of Pyxis Oncology during the first quarter worth about $59,000. Cetera Advisors LLC bought a new stake in Pyxis Oncology during the 1st quarter valued at approximately $100,000. Cable Car Capital LLC purchased a new position in Pyxis Oncology in the 4th quarter worth approximately $111,000. Finally, Susquehanna Fundamental Investments LLC bought a new position in Pyxis Oncology in the 1st quarter worth approximately $351,000. Hedge funds and other institutional investors own 39.09% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on PYXS shares. Stifel Nicolaus assumed coverage on shares of Pyxis Oncology in a research report on Thursday, August 8th. They set a “buy” rating and a $10.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Pyxis Oncology in a research note on Friday, August 16th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $7.00 price target on shares of Pyxis Oncology in a research note on Thursday. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $9.00.

Pyxis Oncology Stock Performance

PYXS stock opened at $3.69 on Friday. The firm has a fifty day moving average price of $3.59 and a 200 day moving average price of $3.99. Pyxis Oncology, Inc. has a fifty-two week low of $1.35 and a fifty-two week high of $6.85. The firm has a market cap of $217.30 million, a PE ratio of -2.71 and a beta of 1.28.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. On average, equities analysts predict that Pyxis Oncology, Inc. will post -1.07 EPS for the current year.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.